
Jan 12 (Reuters) - Travere Therapeutics Inc TVTX.O:
TRAVERE THERAPEUTICS PROVIDES CORPORATE UPDATE AND 2026 OUTLOOK
TRAVERE THERAPEUTICS INC - EXPECTS $127 MILLION U.S. NET PRODUCT SALES IN Q4 2025
TRAVERE THERAPEUTICS INC - EXPECTS $410 MILLION U.S. NET PRODUCT SALES FOR 2025
TRAVERE THERAPEUTICS INC - TO RESTART PHASE 3 HARMONY STUDY IN Q1 2026
TRAVERE THERAPEUTICS INC - PDUFA TARGET DATE FOR FILSPARI APPROVAL IS JANUARY 13, 2026